1. Introduction {#sec1-molecules-21-00161}
===============

The liver is the largest complex organ in the body which plays an important role in the internal environment maintenance by its multiple functions. It plays a central role in the metabolic pathways of carbohydrates, lipids and proteins. It is also involved in the detoxification and excretion of many endogenous and exogenous compounds by its xenobiotic metabolism. An impairment of its function is a serious health problem. Approximately 18,000 people have died per year in India due to liver function impairment \[[@B1-molecules-21-00161]\].

Acetaminophen (*N*-acetyl-*p-*aminophenol; APAP) is widely used as an analgesic and antipyretic drug worldwide. It produces alanine derivatives by hydrolysis, which are directly converted into hydroxylamine. *N*-Acetyl-*p*-benzoquinoneimine (NAPQI), is an intermediate product of acetaminophen produced in the presence of cytochrome-p450 that causes hepatic damage \[[@B2-molecules-21-00161]\] and tubular necrosis in the kidney \[[@B3-molecules-21-00161]\] in both humans and experimental animals \[[@B4-molecules-21-00161]\]. In this situation, a large amount of APAP is metabolized by the presence of P450s, which leads to reduced GSH levels by NAPQI conjugation and covalent binding of NAPQI. Acetaminophen's clinical and biochemical side effects are well known and it is therefore used as a reference compound to assess the strengths and weaknesses of genomic and proteomic technologies as toxicological tools.

Proteomic approaches and complementary global gene expression analysis are important tools for identifying differentially expressed proteins in cells. The protein expression analysis by two dimensional electrophoresis (2DE) and matrix assisted laser desorption/ionization time of flight (MALTI-TOF) were reported for different types of diseases and offered opportunities for identifying new markers and therapeutic targets \[[@B5-molecules-21-00161]\]. Differentially expressed proteins indicates proteins occuring in a specific function that are either the up regulated or down regulated level as compared with normal levels. The differential expression may be a consequence of disease- or disorder-related variations in transcription, translation, transport, degradation and covalent modification \[[@B6-molecules-21-00161]\]. The systematic proteomic approach has been used to identify the proteins which are responsible for abnormal functions in the various cells. Especially, the molecular mechanisms of cell maturation \[[@B7-molecules-21-00161]\] function \[[@B8-molecules-21-00161]\] and pathology \[[@B9-molecules-21-00161]\]. 2D gel electrophoresis was recently used to identify more than 1000 single proteins. The systematic proteomic approach performs different functions like energy production, protein synthesis and turnover, protein folding and transport, cell cycle, apoptosis and oxidative stress, cytoskeleton, flagella movement, signal transduction, cell recognition and metabolism as well as unknown protein functions \[[@B10-molecules-21-00161],[@B11-molecules-21-00161],[@B12-molecules-21-00161]\]. The aim of the present study was to analyze the proteomic changes in male Wistar rat liver associated with toxicity induced by acetaminophen.

2. Results {#sec2-molecules-21-00161}
==========

2.1. Biochemical Analysis {#sec2dot1-molecules-21-00161}
-------------------------

Plasma alanine amino transferase (ALT) and aspartate amino transferase (AST) levels identified by the routine clinical chemistry showed marked increases at the APAP concentration of mg/kg. The results are summarized in [Table 1](#molecules-21-00161-t001){ref-type="table"}.

molecules-21-00161-t001_Table 1

###### 

AST and ALT activity of experimental group of rats.

  Enzymes (IU/L)               Acetaminophen (mg/kg)               
  ---------------------------- ----------------------- ----------- -----------
  Aspartate aminotransferase   139 ± 4.9               115 ± 2.4   251 ± 1.2
  Alanine aminotransferase     083 ± 1.5               076 ± 1.1   130 ± 8.5

The control liver histopathological sections exhibited well preserved hepatocytes, nuclei, and cytoplasms with proper central veins, whereas slightly damaged hepatocytes and improper cytoplasm distribution, and infiltration of inflammatory cells around the central vein were noted in toxic dose-induced rats. Almost similar architecture was showed in non-toxic dose-induced rats ([Figure 1](#molecules-21-00161-f001){ref-type="fig"}).

![Histopathological analysis of experimental liver tissues. **A**---Control, **B**---Non toxic dose, **C**---Toxic dose induced liver tissue. N---Nucleus, H---Hepatocyte, CV---Central vein, IF---Inflammatory cells.](molecules-21-00161-g001){#molecules-21-00161-f001}

2.2. 2D Gel Analysis {#sec2dot2-molecules-21-00161}
--------------------

The proteins in the toxic, non-toxic and normal livers were separated by 2-DE on large format gels (17 × 20 cm, [Figure 2](#molecules-21-00161-f002){ref-type="fig"}). Comparison of the toxic, normal, and non-toxic dosed liver tissues protein profiles revealed significant quantitative and qualitative differences. Twenty three (23) spots were differentially expressed between control *vs.* toxic doses of the liver tissue and 39 spots were differentially expressed between the control *vs*. non-toxic doses of liver tissues, similarly, 32 spots were significantly expressed as differential protein spots between toxic and non-toxic doses.

![2D map of experimental rat liver. Liver proteins were separated by pH gradient 3--10 by 12% SDS-PAGE. **A**---Control, **B**---Non-toxic dose (150 mg/kg), **C**---Toxic dose (1500 mg/kg).](molecules-21-00161-g002){#molecules-21-00161-f002}

Spots in the gel were cut and the corresponding proteins identified were indicated in [Figure 3](#molecules-21-00161-f003){ref-type="fig"}A. The relative expression levels of the proteins in experimental rats were showed in the graphical representation ([Figure 3](#molecules-21-00161-f003){ref-type="fig"}B). It showed their corresponding SSP numbers on the X axis and their relative intensities on Y-axis.

![Master gel image (**A**) and relative expression of proteins (**B**).](molecules-21-00161-g003){#molecules-21-00161-f003}

2.3. Image Analysis {#sec2dot3-molecules-21-00161}
-------------------

Image analysis of the toxic, non-toxic and normal liver tissues showed number of differential proteins that were summarized in the Venn diagram ([Figure 4](#molecules-21-00161-f004){ref-type="fig"}).

![Venn graphical representation of no.of spots in the control, non-toxic and toxic dose rats.](molecules-21-00161-g004){#molecules-21-00161-f004}

2.4. MALDI-TOF Analysis {#sec2dot4-molecules-21-00161}
-----------------------

The 2D gels of toxic, non-toxic and control liver tissues were resolved on 12% SDS-PAGE and then silver stained. The selected protein spots after image analysis were taken from the gel with the listed SSP numbers and analyzed on MALDI-TOF for protein identification by submitting the peptide mass finger print data. All the protein spots were analyzed on Micromass MALDI-TOF in the reflectron mode. Based on peptide mass finger prints, the protein spots were accordingly identified by using the mascot distiller software from Matrix science UK the identified proteins are listed along with their Swissprot accession numbers ([Table 2](#molecules-21-00161-t002){ref-type="table"} and [Table 3](#molecules-21-00161-t003){ref-type="table"}). The identified proteins were classified in the pie chart according to their cellular localization ([Figure 5](#molecules-21-00161-f005){ref-type="fig"}).

molecules-21-00161-t002_Table 2

###### 

Differentially expressed proteins in rats received 150 mg/kg of APAP.

  S. No   SSP    Protein Name                                                   Sequence Coverage (%)   Estimated M.WT   *PI*   Swissprot No
  ------- ------ -------------------------------------------------------------- ----------------------- ---------------- ------ -----------------
  1       4514   Cold-inducible RNA-binding protein                             23                      38               7.0    P60825
  2       3716   CYP2D3                                                         38                      57               6.7    P12938
  3       5910   Tissue factor pathway inhibitor precursor (TFPI)               29                      72               7.6    Q02445
  4       2204   Homeobox protein DRG11                                         21                      28.6             5.9    Q62798
  5       608    SEC14-like protein 3                                           39                                              
  6       3      Low-density lipoprotein receptor-related protein 4 precursor   42                      45.1             4.8    Q9Z1J8
  7       2308   Splice isoform 1; Variant Displayed                            27                      31.6             6.1    Q8VHQ7-00-00-00
  8       2206   Trypsin V-B precursor                                          41                      28               6.1    P32822
  9       5      (NLG1_RAT) Splice isoform                                      32                      13                      Q62765-03-00-00
  10      135    Somatostatin precursor                                         24                      15.4             4.9    P60042
  11      3402   Guanine nucleotide-binding protein G\[I\]                      33                      33               6.4    P54313
  12      7602   Transforming growth factor beta 1 precursor                    38                      48.2             8.4    P17246
  13      4801   Synaptotagmin X                                                47                      60.7             6.8    O08625
  14      7210   (EPOR_RAT) Splice isoform                                      42                      28.2             8.9    Q07303-01-00-00
  15      6412   Sphingosine 1-phosphate receptor Edg-5                         39                      36.6             8.2    P47752
  16      3823   Hydroxymethylglutaryl-CoA synthase,                            35                      60.6             6.8    P17425
  17      5807   Splice isoform Long; Variant Displayed;                        42                      61.57            7.4    Q09137-00-00-00
  18      8101   Trefoil factor 2 precursor                                     19                      15.9                    Q09030
  19      2808   Nonspecific lipid-transfer protein, mitochondrial precursor    34                      61               6\.    P11915
  20      6804   Cyclic-nucleotide-gated olfactory channel                      36                      61.4             7.8    Q64359
  21      3408   Nuclear transcription factor Y subunit gamma                   29                      34.4             6.5    Q62725
  22      6701   Neural Wiskott-Aldrich syndrome protein                        35                      53.2             7.8    O08816
  23      8305   Kinesin heavy chain isoform                                    47                      29                      P56536
  24      2601   P2X purinoceptor 1                                             16                      47.9             5.8    P47824
  25      5108   Synaptosomal-associated protein                                41                      21               7.5    O70377
  26      8101   Phospholipase A2 precursor                                     38                      15.9                    P04055
  27      3409   3,2-trans-enoyl-CoA isomerase,                                 32                      35.5             6.6    P23965
  28      M6     Cytochrome P450                                                54                      60.7             6.8    P30839
  29      5807   Growth factor receptor-bound protein 14                        36                      61.5             7.4    O88900
  30      6710   Methionine aminopeptidase's 2                                  49                      53.2             7.8    P38062
  31      1206   Trypsin I, anionic precursor                                   51                      27.2             5.5    P00762
  32      1103   60 S Ribosomal protein                                         28                      15.5             5.1    P62907
  33      4101   Peripheral myelin protein 22                                   33                      11.9             6.8    Q63199
  34      M1     GST                                                            36                      24.0             4.9    P08011
  35      5215   GSH                                                            47                      24               7.0    P19468

molecules-21-00161-t003_Table 3

###### 

Differentially expressed proteins in rats received 1500 mg/kg of APAP.

  S. No   SSP    Protein Name                                            Sequence Coverage (%)   Score   Estimated M.WT   *PI*   Swissprot No.
  ------- ------ ------------------------------------------------------- ----------------------- ------- ---------------- ------ ---------------
  1       3716   CYP2D3                                                  25                      22      57               6.7    P12938
  2       8305   Homeobox protein DRG11                                  24                      19      29               9.5    Q62798
  3       3705   4-Aminobutyrate aminotransferase                        35                      35      56               6.4    P50554
  4       3312   Serine/threonine protein phosphatase                    32                      34      31.5             6.7    P13353
  5       6101   Acyl CoA                                                41                      39      18.38            7.8    Q64559
  6       5504   ArgininosPuccinate synthase                             38                      32      43.8             7.3    P09034
  7       4801   Synaptotagmin X                                         36                      38      60.7             6.8    O08625
  8       8314   CD82 antigen                                            25                      22      30                      O70352
  9       3823   Hydroxymethylglutaryl-CoA synthase,                     29                      28      60.6             6.8    P17425
  10      3306   F-box/LRR-repeat protein 20                             40                      35      29.4             6.6    Q9QZH7
  11      8301   Suppressor of cytokine signaling 1 (SOCS-1)             36                      32      29.2             9.1    Q9QX78
  12      1403   Calcineurin-binding protein Cabin 1                     34                      31      34.2             5.1    O88480
  13      3115   Hydroxymethylglutaryl-CoA synthase                      33                      28      18.7             6.6    P22791
  14      5712   Lipopolysaccharide-binding protein precursor            45                      41      56               7.5    Q63313
  15      3705   Cytochrome P450                                         46                      40      56.00            6.4    P20812
  16      2908   Liver carboxylesterase B-1 precursor                    35                      32      66.9             6.2    Q63010
  17      5106   Acetyl-CoA acetyltransferase, mitochondrial precursor   33                      34      20.4             7.5    P17764
  18      3908   Hyaluronan synthase 2                                   22                      17      66.4             6.6    O35776
  19      3522   Carbonic anhydrase III                                  25                      21      38.6             6.7    P14141
  20      6019   Cytochrome c oxidase polypeptide VIa-liver              29                      23      14.0             8.3    P10818
  21      2710   CYP2B3                                                  24                      20      54.8             6.3    P13107
  22      4003   Peripheral myelin protein 22                            36                      32      11.9             6.8    Q63199
  23      8705   CYP1A2                                                  37                      35                              P04799
  24      M2     Heat shock protein 70                                   36                      34      70               5.8    Q07439
  25      M3     Aspartate aminotransferase                              30                      33      55               6.1    P13221
  26      M4     Alanine aminotransferase                                27                      21      54                      P25409
  27      M5     IFN gamma                                               23                      26      19               4.8    P01581
  28      501    Mitogen-activated protein kinase                        21                      20      43.4             4.9    Q9WTY9
  29      2710   CYP2B3                                                  28                      24      54.8             6.3    P13107
  30      M6     Cytochrome P450                                         30                      24      60.7             6.8    P30839
  31      8305   Kinesin heavy chain isoform                             33                      32                              
  32      7802   (Pyruvate dehydrogenase (Lipoamide))-phosphatase 2      38                      31      60               8.5    O88484
  33      7602   Transforming growth factor beta 1 precursor             36                      35      48.2             8.4    P17246
  34      7210   Calcium-activated potassium channel beta subunit 2      41                      38      28               8.9    Q811Q0
  35      135    Hippocalcin-like protein                                52                      47      15               4.9    P62749
  36      4002   Cadherin-14 (Fragment) (Rat)                            17                      21      11.0             6.8    Q9Z2V8
  37      3      Single-stranded DNA-binding protein                     20                      25      14                      P28042
  38      850    Splice isoform Displayed                                24                      17      43.4             4.9    Q9R0E0
  39      3512   Wnt-5a protein precursor                                35                      34      41.7             6.5    Q9QXQ7
  40      1204   60S ribosomal protein L7                                21                      20      23               5.3    P37805
  41      3823   Phosphoglucomutase                                      34                      32      60.6             6.8    P38652
  42      8705   Glutamate decarboxylase                                 36                      34      60.5             9.2    P18088

![Classification of differentially expressed proteins based on the localization.](molecules-21-00161-g005){#molecules-21-00161-f005}

The identified proteins were classified according to their putative functions, the percentage of transporter proteins, cell proliferation and differentiation related proteins, transcription and translational proteins, neurological and antioxidants protein were down-regulated in high dose APAP-treated rats as compared with non-toxic dose treated rats, whereas, oxidative stress, urea and TCA cycle, and immunity-related protein expressions were up regulated in higher APAP-treated rats as compared with non-toxic dose-treated rats ([Figure 6](#molecules-21-00161-f006){ref-type="fig"}).

![Classification of proteins based on their putative function extracted from experimental rat livers. **A**---150 mg/kg of APAP-treated rats; **B**---1500 mg/kg of APAP-treated rats.](molecules-21-00161-g006){#molecules-21-00161-f006}

Among the identified proteins in the toxicity induced rats, we have separated differentially expressed proteins that are known to play a vital role in the toxicity assessments, which are summarized in [Table 4](#molecules-21-00161-t004){ref-type="table"}.

molecules-21-00161-t004_Table 4

###### 

High differentially expressed proteins in rats received 1500 mg/kg of APAP.

  S. No   Protein Identified                                      Swiss Port NO   M.WT (Kda)
  ------- ------------------------------------------------------- --------------- ------------
  1       Cytochrome P450                                         P20812          56.00
  2       Heat shock protein70                                    Q07439          70
  3       IFN-γ                                                   P01581          19
  4       Cyp2B3                                                  P13107          54.8
  5       Cyp2D3                                                  P12938          57
  6       AST                                                     P13221          55
  7       ALT                                                     P25409          54
  8       Suppressor of cytokine signaling 1                      Q9QX78          29.2
  9       Liver carboxylesterase B-1 precursor                    Q63010          66.9
  10      Acetyl-CoA acetyltransferase, mitochondrial precursor   P17764          20.4
  11      Cytochrome c oxidase polypeptide VIa-liver              P10818          14.0
  12      Calcineurin-binding protein Cabin 1                     O88480          34.2
  13      Hydroxymethylglutaryl-CoA synthase                      18.7            P22791

3. Discussion {#sec3-molecules-21-00161}
=============

The liver plays an important role in preventing the accumulation of compounds by converting them into a suitable form for elimination. All compounds undergo xenobiotic metabolism, which requires multiple biochemical transformations. During this process some of the intermediates exhibit toxic responses. Generally, the liver is potentially susceptible to injury during the action of intermediate products of compounds or drugs. An improved quantitative understanding of the balance between the xenobiotic detoxification process and hepatic injury could provide guidelines for safe levels in both pharmaceutical and the toxicological conditions. Especially, the ability to predict the toxicity profile of lead candidates is critical to streamlining pharmaceutical drug development \[[@B13-molecules-21-00161]\]. A better understanding of the beginning of liver injury is an opportunity to recognize personalized medicine according to the genetics, active biomarkers and environment of the individual patient \[[@B14-molecules-21-00161]\].

Acetaminophen toxicity is related to the accumulation of toxic intermediate metabolites such as *N*-acetyl-*p*-benzoquinoneimine(NAPQI). Normally, acetaminophen is metabolized into NAPQI by cytochrome P450-dependent mixed-function oxidase in the liver and by the prostaglandin synthetase system in the kidney. Then, these metabolites are detoxified by reduced glutathione (GSH). When glutathione levels are depleted, this intermediate can covalently bind to nucleophilic targets of macromolecules in cells that eventually causes cell death. In the present study, we investigated the effect of acetaminophen on liver proteomic changes in rats. The rats treated with 1500 mg/ kg of body weight exhibited increased activities of AST and ALT. This indicates that acetaminophen induced liver damage at the concentration of 1500 mg/kg. The AST and ALT levels were found higher in the cytoplasm and mitochondria. During liver damage, the transport function of hepatocytes is disturbed and as a result plasma membrane damage ocurrs thereby causing increased activities of these enzymes, further leading to cellular leakage and loss of cellular integrity \[[@B15-molecules-21-00161]\].

The American Liver Foundation reported that 35% of severe liver failures were caused by acetaminophen toxicity. Addition of *N*-acetylcysteine to acetaminophen tablets was proposed to prevent liver toxicity \[[@B16-molecules-21-00161]\]. The protein glutathione *S*-transferase gets up regulated during liver damage induced by excessive doses of acetaminophen. Glutathione transferases(GSTs) are complex enzymes that are involved in many biological functions, especially in detoxification of a large number of electrophilic intermediates. A large amount of electrophilic intermediates is produced by APAP oxidation in the presence of cytochrome P450. The liver is highly susceptible to these intermediates. However, these intermediates are detoxified by reduced glutathione, but higher doses of APAP exhibit more hepatotoxicity that reduce GSH levels and it permit the binding of unconjugated NAPQI to macromolecules in cells \[[@B17-molecules-21-00161],[@B18-molecules-21-00161],[@B19-molecules-21-00161],[@B20-molecules-21-00161]\].

Many possible nucleophilic targets are found in the cells that are bound by the unconjugated NAPQI. This interaction mechanism between the cells and unconjugated NAPQI stimulates the cell death program \[[@B21-molecules-21-00161],[@B22-molecules-21-00161]\]. Cytochrome P450s are responsible for most xenobiotics, and are needed for the proper elimination of toxic chemicals from the body. These enzymes metabolically activate biologically inert compounds into electrophilic derivatives that can cause toxicity, cell death and cancer. Advances in proteomics and genomics are providing a much improved view of the molecular players and pathways involved in the metabolism of xenobiotics. Here, we studied proteomic changes caused by treatment with higher doses of acetaminophen using 2D gel electrophoresis and MALDI-TOF. The results indicated that the percentages of transporter proteins, cell proliferation and differentiation proteins, transcription and translational proteins, neurological proteins and some of the antioxidants were down-regulated in higher APAP-treated rats as compared with non-toxic dose treated ones, whereas, oxidative stress-related proteins, urea and TCA cycle and immunity-related proteins were abundantly expressed in higher APAP-treated rats as compared with non-toxic dose treated rates.

4. Experimental Section {#sec4-molecules-21-00161}
=======================

4.1. Animal Treatment {#sec4dot1-molecules-21-00161}
---------------------

All animal procedures were performed under GLP conditions. Animals were separated into three groups, each consisting of five wild-type adult male Wistar rats (average weight 150--200 g) that were housed in a controlled environment and quarantined for 72 h. Group I received 0.25% CMC (control vehicle), Group II received 150 mg/kg of APAP (nontoxic dose; A5000, Sigma-Aldrich (St. Louis, MO, USA) and Group III received 1500 mg/kg of APAP (toxic dose). After the experiments the animals were sacrificed by the terminal anesthesia method and their liver tissues were removed, frozen in liquid nitrogen and stored at --80 °C.

4.2. Biochemical Analysis {#sec4dot2-molecules-21-00161}
-------------------------

Plasma alanine amino transferase (ALT) and aspartate amino transferase (AST) levels in the plasma toxic, non-toxic and control animals were analyzed by routine clinical chemistry.

4.3. Histopathology Analysis {#sec4dot3-molecules-21-00161}
----------------------------

Portion liver tissues were cut into small species and fixed in 10% formalin solution and then embedded in paraffin wax. The fixed tissues were stained with haematoxylin-eosin \[[@B12-molecules-21-00161]\].

4.4. Protein Sample Preparation {#sec4dot4-molecules-21-00161}
-------------------------------

Liver samples from each animal were processed separately. The whole liver was washed thoroughly in phosphate buffer saline (PBS) and finely sliced with sharp edge knife and homogenized in 5 mL of homogenization buffer I (40 mM Tris, 1 mM phenylmethylsulfonyl fluoride and 20 μL of protease inhibitor cocktail (Sigma)) on ice, with motor and pestle to a fine paste. The protein suspension was centrifuged at 15,000 rpm for 20 min at 4 °C. The pellet was dissolved in 0.5 mL buffer II (40 mM Tris, 8 M Urea, 4% CHAPS, 0.2% Biorad Biolyte \[[@B3-molecules-21-00161],[@B4-molecules-21-00161],[@B5-molecules-21-00161],[@B6-molecules-21-00161],[@B7-molecules-21-00161],[@B8-molecules-21-00161],[@B9-molecules-21-00161],[@B10-molecules-21-00161]\], 2 mM TBP, 2 mM DTT and protease inhibitors cocktail) and centrifuged at 15,000 rpm for 20 min at 15 °C. The supernatants were aliquot and stored at −70 °C. Protein concentrations for each supernatant were estimated by Biorad's RCDC™ method.

4.5. DE and Image Analysis {#sec4dot5-molecules-21-00161}
--------------------------

An equal amount of protein (300 μg) from each sample was diluted in Biorad rehydration buffer (300 µL) of and loaded onto 17 cm, pH 3--10 immobilized pH gradient IPG, strips (Biorad, Philadelphia, PA, USA). The proteins were separated on the first dimension with total of 60 kVh of Isoelectric focusing on rapid ramp using Protean IEF Cell (Biorad). The focused strips were equilibrated in buffer containing 6 M urea, 2% (*w*/*v*) SDS, 0.375 M Tris-HCl, pH 8.8, 20% (*v*/*v*) glycerol, 2.4% (*w*/*v*) acrylamide and 5 mM TBP, for 1 h at room temperature with slight agitation. The equilibrated strips were applied directly to 12.5% SDS-polyacrylamide gels (20 × 24 cm) and separated for 4 hrs at 200 V constant voltages. The gels were fixed in 40% methanol, 10% acetic acid for overnight and stained with silver stain. After rinsing, the gels were scanned with a GS800 calibrated Densitometer scanner (Biorad). Images from two replicate gels with good separation were selected for comprehensive image analysis using the PDQuest software program (Biorad, version-7). Protein profiles of samples extracted with buffer II were only considered for image analysis. Three replicate groups of the gels of control, nontoxic and toxic samples were created. Each replicate group consisted of five gels representing the liver profiles of animals in that set. The gels were normalized for any other variations like background staining, staining times, exposure times *etc.* Spots with average quantitative change greater than 2-fold between the replicate groups were considered statistically significantly regulated spots.

4.6. In-gel Tryptic Digestion and Mass Spectrometry (MALDI-TOF) Analysis {#sec4dot6-molecules-21-00161}
------------------------------------------------------------------------

Spots that were significantly regulated were excised from the 2-D gel with a ProteomeWorks^TM^ spot cutter (Biorad) and placed in 96-well plates.The gel pieces were washed and destained by a mixture of 25 mM ammonium bicarbonate and 50% acetonitrile (3 × 30 min). The destained gel pieces were washed with water and reduced for 1 h at 57 °C using buffer (100 mM ammonium bicarbonate and 10 mM dithiothreitol (DTT)). The spots were then alkylated using buffer (100 mM ammonium bicarbonate and 55 mM iodoacetamide) and incubated in the dark for 30 min at room temperature. The gel pieces were dehydrated with 50 µL of 100% acetonitrile, and then dried under vacuum using the speedvac concentrator for 30 min. To the dried gel pieces, digestion solution (100 ng/µL trypsin) in 50 mM of NH~4~HCO~3~ was added and incubated overnight at 37 °C. The peptides were extracted twice from the gel pieces by adding 100 µL of extraction buffer (50% acetonitrile containing 5% trifluoroacetic acid) and the extracts were concentrated by Speedvac for 1 h. The concentrated mixture was desalted by C-18 Ziptips (Millipore, Temecula, CA, USA). The cleaned peptides crystallized with α-cyano-4-hydroxycinnamic acid (HCCA) matrix solution were analyzed by MALDI-TOF (Micromass, Temecula, CA, USA) mass spectrometry in reflectron mode. A pulsed nitrogen laser of 337 nm was fired to accumulate 100 shots per spectra and the peptide mass fingerprints (PMF) of the samples were generated. The spectra width was narrowed to a range from 500 to 3500 Daltons *m/z*. The spectra were processed (baseline correction, noise removal, deisotoping) by using the Mass Lynx version 3.5 software (Philadelphia, PA, USA). Protein identification was generated by feeding the peptide mass finger print data into the public domain search engines Mascot and MS-Fit and by searches in the Swiss Prot database (<http://www.ebi.ac.uk/uniprot>).

5. Conclusions {#sec5-molecules-21-00161}
==============

In this study, AST, ALT, CYP2B3, heat shock protein 70, cytochrome c oxidase, cytochrome P450, suppressor of cytokine signaling 1, liver carboxylesterase B-1 precursor, acetyl-CoA acetyltransferase, mitochondrial precursor, cytochrome c oxidase polypeptide VIa-liver, calcineurin-binding protein cabin 1, andhydroxymethylglutaryl-CoA synthasewere highly up regulated in toxic dose-treated rats. The overall resultssuggest that overdoses of drug treatments modify the regularmetabolic andmolecular pathways in the liver. These data should be useful to predict the toxicological changes in liver proteins by the overdose of acetaminophen and cholesterol lowering drugs.
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